Company: ELV
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0001156039-25-000057
Chunk: 25

Company: Elevance Health, Inc.
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 8
Chunk 25
---
 for the three months ended March 31, 2025 and 2024 are as follows:Three Months Ended  March 3120252024Net gains (losses):Fixed maturity securities:Gross realized gains from sales$28 $22 Gross realized losses from sales(82)(159)Impairment losses recognized in income(1)(2)Net realized losses from sales of fixed maturity securities(55)(139)Equity securities:Unrealized gains (losses) recognized on equity securities still held at the end of the period(6)2 Net realized (losses) gains recognized on equity securities sold during the period(1)— Net gains (losses) on equity securities(7)2 Other investments:Gross gains5 16 Gross losses(94)(20)Other realized losses recognized in income(311)(25)Net losses on other investments(400)(29)Net losses on investments$(462)$(166)A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited 

-16-

to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.Total proceeds from sales, maturities, calls or redemptions of fixed maturity securities were $3,338 and $5,401 during the three months ended March 31, 2025 and 2024, respectively.Accrued Investment IncomeAt March 31, 2025 and December 31, 2024, accrued investment income totaled $268 and $287, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.Securities Lending ProgramsThe fair value of the cash and securities received as collateral for securities loaned at March 31, 2025 and December 31, 2024 was $2,596 and $2,305, respectively. The collateral received was 102% of the market